Leo's Picato falls at first German HTA hurdle
This article was originally published in Scrip
Executive Summary
In a preliminary assessment, the German Institute for Quality and Efficiency in Health Care (IQWiG) has concluded that Leo Pharma's Picato gel (ingenol mebutate) for actinic keratosis, does not provide any added benefit over diclofenac/hyaluronic acid gel.